Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
EryPharm logo — EryPharm developed a mass production process for cultured re...

EryPharm

EryPharm developed a mass production process for cultured red blood cells as a transfusion product.

Founded 2016 France France 4 employees

General Information

Company Name EryPharm
Founded Year 2016
Location France France
Employees 4
Business Model B2B, B2D, B2G
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with EryPharm. To contact EryPharm, visit erypharm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EryPharm compare?

A PDF of EryPharm and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EryPharm soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EryPharm

EryPharm, founded in 2016, is a pioneering biotech startup headquartered in France. The company has developed an innovative large-scale process for producing cultured red blood cells from stem cells, a project initially spearheaded by Dr. Luc Douay and his team at the Paris Sorbonne University.

EryPharm’s technology presents a breakthrough in the field of transfusion products, potentially reshaping the landscape of blood supply. Their approach addresses the perennial challenge of blood donation shortages, proposing a reliable and sustainable alternative.

The company received a seed round investment of €16.38M in July 2016, backed by investors AGORANOV and Corely. Given the foundational technology and significant early investment, EryPharm stands as a compelling prospect for further rounds of financing. This positions them well to escalate their production capabilities and drive market entry in the biotechnology sector.

Business keywords: Biotech, Stem Cell Technology, Blood Transfusion, Cultured Red Blood Cells, Therapeutic Products, Medical Innovation, Biomedical Engineering, Life Sciences, Research and Development

Services & Products

Mass production of cultured red blood cells
Development of new blood transfusion products
Innovative biotechnological approaches

Target Customers

Patients with hereditary blood disorders Cancer patients requiring multiple transfusions Healthcare providers Medical research facilities

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Spinout Undisclosed 1
AGORANOV
AGORANOV
01 Aug 2016

EryPharm Alternatives & Competitors

View All Alternatives
EryPharm vs
OXYVITA Inc.
OXYVITA Inc. United States

Experience a clinically useful blood substitute that dramatically reduces reliance on human donors a...

3 employees
Biotechnology, Health Care
EryPharm vs
Fuji Systems Corporation
Fuji Systems Corporation Japan

Fuji Systems, established in 1963, is a company to development and production of medical devices mad...

9 employees
Manufacturing, Medical Devices
EryPharm vs
CORD:USE Cord Blood Bank Inc.
CORD:USE Cord Blood Bank Inc.

Nearly half a million parents from 87 countries chose to trust Cryo-Cell - Cord Blood Banking Leader...

Debt Financing
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About EryPharm

EryPharm developed a mass production process for cultured red blood cells as a transfusion product.
EryPharm was founded in 2016.
EryPharm is headquartered in France.
EryPharm has a B2B, B2D and B2G business model. Its revenue comes from Product Sales and Licensing.
EryPharm has approximately 4 employees.
EryPharm has completed 1 funding round.
EryPharm offers: Mass production of cultured red blood cells, Development of new blood transfusion products, Innovative biotechnological approaches.
Top alternatives and competitors to EryPharm include OXYVITA Inc., Fuji Systems Corporation, CORD:USE Cord Blood Bank Inc., Neuralstem, Inc., TRELYS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EryPharm and OXYVITA Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EryPharm, https://bouncewatch.com/company/erypharm, updated 24 January 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout